Workflow
The Oncology Institute and SilverSummit Healthplan Partner to Provide Oncology Care to Over 80,000 Medicaid Members in Nevada
Globenewswire· 2025-07-01 04:05
CERRITOS, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI”), one of the largest value-based oncology groups in the United States, announced today that effective July 1, it will be the exclusive oncology provider for over 80,000 Medicaid patients associated with SilverSummit Healthplan in Nevada. TOI is known for bringing state-of-the-art cancer care to the communities it serves, and their presence in the Las Vegas market will provide enhanced access to care and hig ...
Industry First -- Supermicro Systems Certified by Intel for an Immersion Cooling Solution
Prnewswire· 2025-07-01 04:05
文章核心观点 - 超微电脑公司(Supermicro)的BigTwin服务器获英特尔和开放计算项目(OCP)浸没式冷却认证,该认证服务器可降低数据中心能耗和环境影响,满足行业对高效冷却解决方案的需求 [1][3][8] 公司合作与认证 - 超微与英特尔长期战略协作,结合英特尔处理器技术和超微高性能解决方案 [2] - 英特尔携手超微及关键供应商,使超微BigTwin系统通过浸没式冷却严格测试,获英特尔数据中心浸没式冷却认证 [4] - 超微作为OCP顾问委员会成员,在OCP社区发挥关键作用,其BigTwin服务器符合OCP浸没式冷却规范 [4][5] 产品特点与优势 - 超微浸没式认证服务器利用先进浸没式冷却技术,可显著降低电力使用效率(PUE),减少能源成本和环境影响 [3] - 超微BigTwin服务器架构为高密度、多节点平台,与英特尔数据中心液体浸没式冷却解决方案搭配,兼具计算能力和热管理优势 [7] - 超微BigTwin服务器可靠性高,能实现更好的热管理和运营效率,使数据中心达到接近1.05或更低的PUE值 [3][5] 市场需求与趋势 - 随着人工智能和高性能计算应用对处理器性能要求提高,数据中心对浸没式认证服务器需求增长,浸没式冷却比传统风冷更高效可持续 [8] 公司介绍 - 超微是全球应用优化型整体IT解决方案领导者,提供服务器、AI、存储等产品和服务,产品设计制造内部完成,注重降低总体拥有成本和环境影响 [9] 产品规格 - BigTwin® SuperServer SYS - 221BT - HNTR为2U外形,有四个热插拔系统,支持5th/4th Gen英特尔至强可扩展处理器等 [11]
Yorkville Acquisition Corp. Announces Closing of $172,500,000 Initial Public Offering, Including Full Exercise of Underwriters’ Over-Allotment Option
Globenewswire· 2025-07-01 04:05
Mountainside, NJ, June 30, 2025 (GLOBE NEWSWIRE) -- Yorkville Acquisition Corp. (Nasdaq: YORKU) (the “Company”) today announced that it closed its initial public offering of 17,250,000 units, including the issuance of 2,250,000 units as result of the underwriters’ exercise of their over-allotment option in full, at $10.00 per unit. The gross proceeds from the offering were $172.5 million before deducting underwriting discounts and estimated offering expenses. The units began trading on The Nasdaq Global Mar ...
CNB Financial Corporation and ESSA Bancorp, Inc. Receive Bank Regulatory Approvals for Merger
Globenewswire· 2025-07-01 04:05
CLEARFIELD, Pa. and STROUDSBURG, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- CNB Financial Corporation (“CNB”) (NASDAQ: CCNE) and ESSA Bancorp Inc. (“ESSA”) (NASDAQ: ESSA) are pleased to announce that they have received the necessary bank regulatory approvals to complete the proposed merger (the “Merger”) of ESSA with and into CNB and ESSA Bank & Trust (“ESSA Bank”) with and into CNB Bank (“CNB Bank”). The Federal Deposit Insurance Corporation and the Pennsylvania Department of Banking and Securities approved th ...
Bank OZK Announces Date for Second Quarter 2025 Earnings Release and Conference Call
Globenewswire· 2025-07-01 04:01
LITTLE ROCK, Ark., June 30, 2025 (GLOBE NEWSWIRE) -- Bank OZK (the “Bank”) (Nasdaq: OZK) expects to report its second quarter 2025 earnings after the market closes on Thursday, July 17, 2025. Management’s comments on the second quarter of 2025 will be released simultaneously with the earnings press release and financial supplement which will be available on the Bank’s investor relations website. Management will conduct a conference call to take questions at 7:30 a.m. CT (8:30 a.m. ET) on Friday, July 18, 2 ...
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
Globenewswire· 2025-07-01 04:01
文章核心观点 公司宣布在《临床癌症研究》上发表givastomig单药治疗的首个人体数据,该数据显示givastomig单药治疗在Claudin 18.2阳性胃癌患者中取得了一定疗效,且耐受性良好,支持其与标准免疫化疗联合作为一线治疗方案的开发 [1][3] 研究基本信息 - 研究对象为75名胃癌或其他实体瘤患者,其中43名可评估疗效的CLDN18.2阳性晚期或转移性胃食管癌患者 [2] - 患者接受givastomig治疗,剂量范围为0.1 - 18 mg/kg,分九个连续剂量水平给药 [5] - 患者既往接受过大量治疗,中位治疗线数为三线,75%的患者为CLDN18.2阳性 [5] 研究结果 疗效数据 - 43名可评估疗效的CLDN18.2阳性晚期或转移性GEC患者接受givastomig单药治疗,客观缓解率(ORR)为16%(7/43),疾病控制率(DCR)为49%(21/43) [6][7] - 数据截止后,又有两名患者入组单药治疗研究,新增一例确认部分缓解(PR),ORR提高至18%(8/45) [2] - 缓解者的CLDN18.2表达范围为11% - 100%,表明givastomig在低水平CLDN18.2表达的肿瘤中也有活性 [2][15] 安全性数据 - 至15 mg/kg每两周一次(Q2W)和18 mg/kg每三周一次(Q3W)未报告剂量限制性毒性,未确定最大耐受剂量(MTD) [15] - 最常见的治疗相关不良事件(TRAEs)主要为1级或2级 [15] 药代动力学数据 - givastomig在剂量≥5 mg/kg时表现出线性药代动力学(PK),可溶性4 - 1BB水平呈剂量依赖性增加,在8 - 18 mg/kg剂量范围内达到平台期 [15] 药物特点及优势 - givastomig是一种靶向Claudin 18.2阳性肿瘤细胞的双特异性抗体,可通过4 - 1BB信号通路在肿瘤微环境中激活T细胞 [9][12] - 与其他Claudin 18.2靶向药物相比,givastomig疗效更好、毒性更低,其独特的双特异性设计使其对Claudin 18.2阳性癌细胞具有高结合亲和力,并通过4 - 1BB实现精细调节的局部T细胞刺激 [4] - 通过精心设计,givastomig的Fc效应器功能被沉默,导致胃肠道毒性低于其他具有完整该功能的Claudin 18.2药物 [4] 研究进展及计划 - 正在进行的1b期研究评估givastomig与标准治疗药物nivolumab加化疗联合用于一线治疗胃癌,剂量递增阶段已完成,第一个剂量扩展队列(n = 20)提前完成入组,第二个剂量扩展队列(n = 20)入组也在提前进行 [10] - 公司预计在2025年第四季度的一次大型医学会议上分享45名患者的更新单药治疗数据集 [2] - 正在进行的剂量递增联合研究数据将于2025年7月2日在西班牙巴塞罗那举行的ESMO胃肠道癌症大会上以小型口头报告形式展示 [3][4] 公司信息 - I - Mab是一家美国的全球生物技术公司,专注于开发精准免疫肿瘤药物治疗癌症,其差异化产品线以givastomig为主导 [1][12] - givastomig由I - Mab与ABL Bio全球合作开发,I - Mab为牵头方,与ABL Bio平分除大中华区和韩国以外的全球权利 [11]
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital
Globenewswire· 2025-07-01 04:01
- $100 million funded upfront; additional $175 million tied to milestones provides strategic flexibility through key inflection points - WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced it has entered into a $275 million non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC), a leader i ...
The Herzfeld Caribbean Basin Fund, Inc. Pays Distribution
Globenewswire· 2025-07-01 04:00
MIAMI BEACH, Fla., June 30, 2025 (GLOBE NEWSWIRE) -- The Herzfeld Caribbean Basin Fund, Inc. (NASDAQ: CUBA) (the “Fund”) today announced that the Fund has made the following distribution pursuant to the Fund’s Managed Distribution Policy (the “Policy”): Declaration DateEx-DateRecord DatePayment DatePer Share05/09/202505/23/202505/23/202506/30/2025$0.2325 The distribution for stockholders has been paid in cash or shares of the Fund’s common stock at the election of stockholders. The total amount of cash dist ...
Kirby Corporation Announces Date for 2025 Second Quarter Earnings Release and Earnings Webcast
Globenewswire· 2025-07-01 04:00
文章核心观点 公司将于2025年7月31日上午6点(中部夏令时)公布2025年第二季度财报,并于上午7点30分进行财报电话会议网络直播 [1] 公司信息 - 公司是美国最大的国内油轮驳船运营商,通过KMT部门运输石化产品、黑油、精炼石油产品和农用化学品等,还参与美国沿海干散货商品运输 [4] - 公司通过KDS部门为发动机、变速器等设备提供售后市场服务和原厂替换零件,还出租设备并制造和再制造专业设备 [4] 会议安排 - 想通过电话参与问答环节的听众需在Kirby Earnings Call Registration预注册,注册者将获得拨入信息和PIN码 [2] - 可访问公司网站www.kirbycorp.com收听网络直播,直播回放将在网站保留一年 [2] - 电话会议讨论的财务和其他信息将在2025年第二季度新闻稿和8 - K表格中公布,文件会在会议前发布在公司网站 [3] 联系方式 - 联系人Kurt Niemietz,联系电话713 - 435 - 1077 [5]
L.B. Foster Company Completes Successful Amendment to its Revolving Credit Agreement
Globenewswire· 2025-07-01 04:00
文章核心观点 公司于2025年6月27日签订第五次修订和重述信贷协议,延长到期日、增加借款能力、改善定价并减少公司融资交易限制,体现公司战略转型成果,为核心业务增长提供支持 [1][2] 信贷协议情况 - 借款能力从1.3亿美元扩大到1.5亿美元,还有6000万美元增量贷款特征可用 [5] - 信贷安排到期日延长五年至2030年6月27日,定价网格得到改善 [5] - 修订条款为投资增长计划和公司融资举措提供更大灵活性 [5] - 信贷协议可用于营运资金融资、资本支出、信用证发行、允许的收购和一般公司用途 [1] 公司情况 - 公司是为铁路和基础设施市场提供产品和服务的全球技术解决方案提供商,成立于1902年,在北美、南美、欧洲和亚洲设有办事处 [3] - 公司的五家银行银团由PNC银行牵头,美国银行、公民银行、富国银行作为联合银团代理,美元银行作为参与者 [2] 公司高管观点 - 公司执行副总裁兼首席财务官对信贷协议修订结果满意,认为改善了整体融资成本、减少限制并增加借款能力,体现公司盈利能力和增长状况的改善,对核心业务机会乐观,感谢相关团队和银行合作伙伴 [2]